Bicycle Therapeutics Plc logo

Bicycle Therapeutics Plc share price today

(BCYC)

Bicycle Therapeutics Plc share price is $14.68 & ₹1,247.45 as on 21 Dec 2024, 2.30 'hrs' IST

$14.68

▲

-0.32

(-2.13%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Bicycle Therapeutics Plc share price in Dollar and Rupees. Guide to invest in Bicycle Therapeutics Plc from India. Also see the sentimental analysis on Indian investors investing in Bicycle Therapeutics Plc. Get details on the Indian mutual funds that are investing in Bicycle Therapeutics Plc. Get Analyst recommendations and forecasts along with all the Bicycle Therapeutics Plc's financials.

Bicycle Therapeutics Plc share price movements

  • Today's Low: $14.66
    Today's High: $15.28

    Day's Volatility :4.06%

  • 52 Weeks Low: $12.17
    52 Weeks High: $28.67

    52 Weeks Volatility :57.55%

Bicycle Therapeutics Plc Returns

PeriodBicycle Therapeutics PlcSector (Health Care)Index (Russel 2000)
3 Months
-38.76%
-11.1%
0.0%
6 Months
-28.56%
-6.0%
0.0%
1 Year
-21.37%
2.7%
0.0%
3 Years
-75.22%
0.6%
-19.7%

Bicycle Therapeutics Plc Key Statistics

in dollars & INR

Previous Close
$15.0
Open
$15.0
Today's High
$15.28
Today's Low
$14.66
Market Capitalization
$1.0B
Today's Volume
$444.7K
52 Week High
$28.670102
52 Week Low
$12.17
Revenue TTM
$36.9M
EBITDA
$-189.3M
Earnings Per Share (EPS)
$-3.28
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-26.67%

How to invest in Bicycle Therapeutics Plc from India?

It is very easy for Indian residents to invest directly in Bicycle Therapeutics Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bicycle Therapeutics Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bicycle Therapeutics Plc or BCYC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bicycle Therapeutics Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bicycle Therapeutics Plc shares which would translate to 0.058 fractional shares of Bicycle Therapeutics Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Bicycle Therapeutics Plc, in just a few clicks!

Returns in Bicycle Therapeutics Plc for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Bicycle Therapeutics Plc investment value today

Current value as on today

₹1,23,567

Returns

₹23,567

(+23.57%)

Returns from Bicycle Therapeutics Plc Stock

₹21,371 (false-21.37%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Bicycle Therapeutics Plc

200%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Bicycle Therapeutics Plc on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 200% more investors are searching Bicycle Therapeutics Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Bicycle Therapeutics Plc

  • Baker Bros Advisors LP

    13.61%

  • Deep Track Capital, LP

    5.14%

  • FCPM III SERVICES BV

    3.39%

  • RA Capital Management, LLC

    3.26%

  • Armistice Capital, LLC

    2.83%

  • Westfield Capital Management Company, L.P.

    2.68%

Analyst Recommendation on Bicycle Therapeutics Plc

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 18 Wall street analysts offering stock ratings for Bicycle Therapeutics Plc(by analysts ranked 0 to 5 stars)

Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Bicycle Therapeutics Plc

What analysts predicted

Upside of 127.27%

Current:

$14.68

Target:

$33.36

Insights on Bicycle Therapeutics Plc

  • Price Movement

    In the last 7 days, BCYC stock has moved up by 6.3%

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 19.51M → 2.67M (in $), with an average decrease of 61.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -26.54M → -50.80M (in $), with an average decrease of 38.8% per quarter

  • BCYC vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 55.6%

  • BCYC vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 97.3%

  • Price to Sales

    ForBCYC every $1 of sales, investors are willing to pay $20.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Bicycle Therapeutics Plc Financials in INR & Dollars

FY18Y/Y Change
Revenue
$7.1M
↑ 246.41%
Net Income
$-21.8M
↑ 34.36%
Net Profit Margin
-306.14%
↑ 483.13%
FY19Y/Y Change
Revenue
$13.8M
↑ 93.4%
Net Income
$-30.6M
↑ 40.11%
Net Profit Margin
-221.78%
↑ 84.36%
FY20Y/Y Change
Revenue
$10.4M
↓ 24.72%
Net Income
$-51.0M
↑ 66.66%
Net Profit Margin
-490.95%
↓ 269.17%
FY21Y/Y Change
Revenue
$11.7M
↑ 12.58%
Net Income
$-66.8M
↑ 30.99%
Net Profit Margin
-571.25%
↓ 80.3%
FY22Y/Y Change
Revenue
$14.5M
↑ 23.65%
Net Income
$-112.7M
↑ 68.69%
Net Profit Margin
-779.35%
↓ 208.1%
FY23Y/Y Change
Revenue
$27.0M
↑ 86.52%
Net Income
$-180.7M
↑ 60.28%
Net Profit Margin
-669.72%
↑ 109.63%
Q2 FY23Q/Q Change
Revenue
$11.4M
↑ 132.78%
Net Income
$-42.6M
↑ 9.06%
Net Profit Margin
-373.81%
↑ 424.07%
Q3 FY23Q/Q Change
Revenue
$5.4M
↓ 53.04%
Net Income
$-49.9M
↑ 17.12%
Net Profit Margin
-932.32%
↓ 558.51%
Q4 FY23Q/Q Change
Revenue
$5.3M
↓ 0.39%
Net Income
$-49.1M
↓ 1.6%
Net Profit Margin
-921.01%
↑ 11.31%
Q1 FY24Q/Q Change
Revenue
$19.5M
↑ 266.14%
Net Income
$-26.5M
↓ 45.93%
Net Profit Margin
-136.01%
↑ 785.0%
Q2 FY24Q/Q Change
Revenue
$9.4M
↓ 51.99%
Net Income
$-39.9M
↑ 50.13%
Net Profit Margin
-425.3%
↓ 289.29%
Q3 FY24Q/Q Change
Revenue
$2.7M
↓ 71.45%
Net Income
$-50.8M
↑ 27.46%
Net Profit Margin
-1.9K%
↓ 1473.13%
FY18Y/Y Change
Profit
$7.1M
↑ 246.41%
FY19Y/Y Change
Profit
$13.8M
↑ 93.4%
FY20Y/Y Change
Profit
$-22.8M
↓ 264.91%
FY21Y/Y Change
Profit
$-33.2M
↑ 45.8%
FY22Y/Y Change
Profit
$10.8M
↓ 132.48%
FY23Y/Y Change
Profit
$20.5M
↑ 90.32%
Q2 FY23Q/Q Change
Profit
$9.7M
↑ 193.15%
Q3 FY23Q/Q Change
Profit
$3.7M
↓ 62.33%
Q4 FY23Q/Q Change
Profit
$3.7M
↓ 0.25%
Q1 FY24Q/Q Change
Profit
$17.9M
↑ 387.68%
Q2 FY24Q/Q Change
Profit
$7.7M
↓ 56.73%
Q3 FY24Q/Q Change
Profit
$481.7K
↓ 93.77%
FY18Y/Y Change
Operating Cash Flow
$-26.1M
↑ 1742.97%
Investing Cash Flow
$-1.2M
↑ 6.56%
Financing Cash Flow
$25.4M
↓ 56.06%
FY19Y/Y Change
Operating Cash Flow
$-28.6M
↑ 9.72%
Investing Cash Flow
$-1.6M
↑ 31.11%
Financing Cash Flow
$58.4M
↑ 129.81%
FY20Y/Y Change
Operating Cash Flow
$-17.8M
↓ 37.83%
Investing Cash Flow
$-1.2M
↓ 22.83%
Financing Cash Flow
$62.8M
↑ 7.53%
FY21Y/Y Change
Operating Cash Flow
$-14.8M
↓ 16.84%
Investing Cash Flow
$-2.0M
↑ 69.17%
Financing Cash Flow
$320.7M
↑ 410.36%
FY22Y/Y Change
Operating Cash Flow
$-86.1M
↑ 482.07%
Investing Cash Flow
$-19.0M
↑ 835.32%
Financing Cash Flow
$6.7M
↓ 97.91%
Q2 FY23Q/Q Change
Operating Cash Flow
$34.1M
↓ 173.47%
Investing Cash Flow
$-277.0K
↑ 0.0%
Financing Cash Flow
$12.3M
↑ 352.24%
Q3 FY23Q/Q Change
Operating Cash Flow
$-1.0M
↓ 103.01%
Investing Cash Flow
$-502.0K
↑ 81.23%
Financing Cash Flow
$234.6M
↑ 1808.81%

Bicycle Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Bicycle Therapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Bicycle Therapeutics Plc Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc
-27.54%
-28.56%
-21.37%
-75.22%
83.04%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.73%
-34.03%
-17.11%
13.66%
87.56%
Biontech Se
Biontech Se
4.48%
30.56%
7.36%
-56.46%
225.6%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-0.55%
10.11%
28.49%
30.99%
109.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-11.79%
-16.36%
-1.97%
78.33%
80.59%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc
NA
NA
NA
-3.05
-0.27
-0.15
NA
12.04
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
17.51
17.51
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.17
0.55
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc
Buy
$1.0B
83.04%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$77.8B
87.56%
17.51
33.61%
Biontech Se
Biontech Se
Buy
$26.7B
225.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.8B
109.19%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.1B
80.59%
32.84
-4.51%

About Bicycle Therapeutics Plc

bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
Organization
Bicycle Therapeutics Plc
Employees
284
CEO
Dr. Kevin Lee M.B.A., Ph.D.
Industry
Biotechnology

Management People of Bicycle Therapeutics Plc

NameTitle
Dr. Kevin Lee M.B.A., Ph.D.
CEO & Executive Director
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE
Co-Founder & Non-Executive Director
Ms. Alethia Rene Young
Chief Financial Officer
Dr. Santiago Arroyo M.D., Ph.D.
Chief Development Officer
Dr. Christian Heinis
Scientific Founder
Mr. Alistair Milnes
Chief Operating Officer
Mr. Travis Thompson
Senior VP, Chief Accounting Officer & Principal Accounting Officer
Dr. Michael Skynner B.sc. Ph.d., Ph.D.
Chief Technology Officer
Ms. Stephanie Yao
Senior Vice President of Investor Relations and Corporate Communications
Mr. Zafar Qadir
Chief Legal Officer & General Counsel

Important FAQs about investing in Bicycle Therapeutics Plc from India :

What is Bicycle Therapeutics Plc share price today?

Bicycle Therapeutics Plc share price today stands at $14.68, Open: $15.00 ; Previous Close: $15.00 ; High: $15.28 ; Low: $14.66 ; 52 Week High: $28.67 ; 52 Week Low: $12.17. The stock opens at $15.00, after a previous close of $15.00. The stock reached a daily high of $15.28 and a low of $14.66, with a 52-week high of $28.67 and a 52-week low of $12.17.

Can Indians buy Bicycle Therapeutics Plc shares?

Yes, Indians can invest in the Bicycle Therapeutics Plc (BCYC) from India.

With INDmoney, you can buy Bicycle Therapeutics Plc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Bicycle Therapeutics Plc at zero transaction cost.

How can I buy Bicycle Therapeutics Plc shares from India?

It is very easy to buy Bicycle Therapeutics Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bicycle Therapeutics Plc be purchased?

Yes, you can buy fractional shares of Bicycle Therapeutics Plc with INDmoney app.

What are the documents required to start investing in Bicycle Therapeutics Plc stocks?

To start investing in Bicycle Therapeutics Plc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Bicycle Therapeutics Plc

Today’s highest price of Bicycle Therapeutics Plc (BCYC) is $15.28.

Today’s lowest price of Bicycle Therapeutics Plc (BCYC) is $14.66.

What is today's market capitalisation of Bicycle Therapeutics Plc

Today's market capitalisation of Bicycle Therapeutics Plc BCYC is 1.0B

What is the 52 Week High and Low Range of Bicycle Therapeutics Plc

  • 52 Week High

    $28.67

  • 52 Week Low

    $12.17

What are the historical returns of Bicycle Therapeutics Plc?

  • 1 Month Returns

    -27.54%

  • 3 Months Returns

    -28.56%

  • 1 Year Returns

    -21.37%

  • 5 Years Returns

    83.04%

Who is the Chief Executive Officer (CEO) of Bicycle Therapeutics Plc

Dr. Kevin Lee M.B.A., Ph.D. is the current Chief Executive Officer (CEO) of Bicycle Therapeutics Plc.